Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.
Mordmüller B, Szywon K, Greutelaers B, Esen M, Mewono L, Treut C, Mürbeth RE, Chilengi R, Noor R, Kilama WL, Imoukhuede EB, Imbault N, Leroy O, Theisen M, Jepsen S, Milligan P, Fendel R, Kremsner PG, Issifou S. Mordmüller B, et al. Among authors: leroy o. Vaccine. 2010 Sep 24;28(41):6698-703. doi: 10.1016/j.vaccine.2010.07.085. Epub 2010 Aug 7. Vaccine. 2010. PMID: 20696154 Free PMC article. Clinical Trial.
Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
Sirima SB, Nébié I, Ouédraogo A, Tiono AB, Konaté AT, Gansané A, Dermé AI, Diarra A, Ouédraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O. Sirima SB, et al. Among authors: leroy o. Vaccine. 2007 Mar 30;25(14):2723-32. doi: 10.1016/j.vaccine.2006.05.090. Epub 2006 Jun 16. Vaccine. 2007. PMID: 17280744 Clinical Trial.
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R. Roestenberg M, et al. Among authors: leroy o. PLoS One. 2008;3(12):e3960. doi: 10.1371/journal.pone.0003960. Epub 2008 Dec 18. PLoS One. 2008. PMID: 19093004 Free PMC article. Clinical Trial.
Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate.
Esen M, Kremsner PG, Schleucher R, Gässler M, Imoukhuede EB, Imbault N, Leroy O, Jepsen S, Knudsen BW, Schumm M, Knobloch J, Theisen M, Mordmüller B. Esen M, et al. Among authors: leroy o. Vaccine. 2009 Nov 16;27(49):6862-8. doi: 10.1016/j.vaccine.2009.09.011. Epub 2009 Sep 13. Vaccine. 2009. PMID: 19755144 Clinical Trial.
Towards validated assays for key immunological outcomes in malaria vaccine development.
OPTIMALVAC consortium; Cavanagh DR, Dubois PM, Holtel A, Kisser A, Leroy O, Locke E, Moorthy VS, Remarque EJ, Shi YP. OPTIMALVAC consortium, et al. Among authors: leroy o. Vaccine. 2011 Apr 12;29(17):3093-5. doi: 10.1016/j.vaccine.2011.01.070. Epub 2011 Feb 4. Vaccine. 2011. PMID: 21296116 Free article. No abstract available.
510 results